PMID- 36516219
OWN - NLM
STAT- MEDLINE
DCOM- 20221216
LR  - 20230110
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 17
IP  - 12
DP  - 2022
TI  - THP-1 cells transduced with CD16A utilize Fcgamma receptor I and III in the 
      phagocytosis of IgG-sensitized human erythrocytes and platelets.
PG  - e0278365
LID - 10.1371/journal.pone.0278365 [doi]
LID - e0278365
AB  - Fc gamma receptors (FcgammaRs) are critical effector receptors for immunoglobulin G 
      (IgG) antibodies. On macrophages, FcgammaRs mediate multiple effector functions, 
      including phagocytosis, but the individual contribution of specific FcgammaRs to 
      phagocytosis has not been fully characterized. Primary human macrophage 
      populations, such as splenic macrophages, can express FcgammaRI, FcgammaRIIA, and 
      FcgammaRIIIA. However, there is currently no widely available monocyte or macrophage 
      cell line expressing all these receptors. Common sources of monocytes for 
      differentiation into macrophages, such as human peripheral blood monocytes and 
      the monocytic leukemia cell line THP-1, generally lack the expression of FcgammaRIIIA 
      (CD16A). Here, we utilized a lentiviral system to generate THP-1 cells stably 
      expressing human FcgammaRIIIA (CD16F158). THP-1-CD16A cells treated with phorbol 
      12-myristate 13-acetate for 24 hours phagocytosed anti-D-opsonized human red 
      blood cells primarily utilizing FcgammaRI with a lesser but significant contribution 
      of IIIA while phagocytosis of antibody-opsonized human platelets equally utilized 
      FcgammaRI and Fcgamma IIIA. Despite the well-known ability of FcgammaRIIA to bind IgG in cell 
      free systems, this receptor did not appear to be involved in either RBC or 
      platelet phagocytosis. These transgenic cells may constitute a valuable tool for 
      studying macrophage FcgammaR utilization and function.
CI  - Copyright: (c) 2022 Gil Gonzalez et al. This is an open access article distributed 
      under the terms of the Creative Commons Attribution License, which permits 
      unrestricted use, distribution, and reproduction in any medium, provided the 
      original author and source are credited.
FAU - Gil Gonzalez, Lazaro
AU  - Gil Gonzalez L
AUID- ORCID: 0000-0002-3042-8919
AD  - Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity 
      Health Toronto, Toronto ON, Canada.
FAU - Fernandez-Marrero, Yuniel
AU  - Fernandez-Marrero Y
AD  - Biological Sciences, Sunnybrook Research Institute, Toronto, ON, Canada.
FAU - Norris, Peter Alan Albert
AU  - Norris PAA
AD  - Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity 
      Health Toronto, Toronto ON, Canada.
AD  - Innovation and Portfolio Management, Canadian Blood Services, Ottawa, ON, Canada.
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto, 
      Toronto, ON, Canada.
FAU - Tawhidi, Zoya
AU  - Tawhidi Z
AD  - Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity 
      Health Toronto, Toronto ON, Canada.
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto, 
      Toronto, ON, Canada.
FAU - Shan, Yuexin
AU  - Shan Y
AD  - Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity 
      Health Toronto, Toronto ON, Canada.
FAU - Cruz-Leal, Yoelys
AU  - Cruz-Leal Y
AUID- ORCID: 0000-0003-2350-1855
AD  - Innovation and Portfolio Management, Canadian Blood Services, Ottawa, ON, Canada.
FAU - Won, Kevin Doyoon
AU  - Won KD
AUID- ORCID: 0000-0002-1457-3948
AD  - Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity 
      Health Toronto, Toronto ON, Canada.
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto, 
      Toronto, ON, Canada.
FAU - Frias-Boligan, Kayluz
AU  - Frias-Boligan K
AD  - Innovation and Portfolio Management, Canadian Blood Services, Ottawa, ON, Canada.
FAU - Branch, Donald R
AU  - Branch DR
AD  - Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity 
      Health Toronto, Toronto ON, Canada.
AD  - Innovation and Portfolio Management, Canadian Blood Services, Ottawa, ON, Canada.
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto, 
      Toronto, ON, Canada.
AD  - Department of Medicine, University of Toronto, Toronto, ON, Canada.
FAU - Lazarus, Alan H
AU  - Lazarus AH
AD  - Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity 
      Health Toronto, Toronto ON, Canada.
AD  - Innovation and Portfolio Management, Canadian Blood Services, Ottawa, ON, Canada.
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto, 
      Toronto, ON, Canada.
AD  - Department of Medicine, University of Toronto, Toronto, ON, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221214
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Receptors, IgG)
RN  - 0 (Immunoglobulin G)
SB  - IM
MH  - Humans
MH  - *Receptors, IgG/metabolism
MH  - *Immunoglobulin G
MH  - THP-1 Cells
MH  - Phagocytosis
MH  - Monocytes/metabolism
MH  - Erythrocytes/metabolism
PMC - PMC9749970
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/12/15 06:00
MHDA- 2022/12/17 06:00
PMCR- 2022/12/14
CRDT- 2022/12/14 13:52
PHST- 2022/07/04 00:00 [received]
PHST- 2022/11/15 00:00 [accepted]
PHST- 2022/12/14 13:52 [entrez]
PHST- 2022/12/15 06:00 [pubmed]
PHST- 2022/12/17 06:00 [medline]
PHST- 2022/12/14 00:00 [pmc-release]
AID - PONE-D-22-18939 [pii]
AID - 10.1371/journal.pone.0278365 [doi]
PST - epublish
SO  - PLoS One. 2022 Dec 14;17(12):e0278365. doi: 10.1371/journal.pone.0278365. 
      eCollection 2022.